News for Amicus Therapeutics, Inc. (FOLD)

Significant Transaction by PERCEPTIVE ADVISORS LLC (Trades, Portfolio) On January 8, 2025, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a noteworthy tra

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amicus Therapeutics, Inc.

Significant Acquisition by PERCEPTIVE ADVISORS LLC (Trades, Portfolio) On February 13, 2025, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) made a notable addition

On February 19, 2025, Perceptive Advisors LLC made a significant move by acquiring an additional 5,028,033 shares of Solid Biosciences Inc (SLDB). This transact

Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The following slide deck was published by Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ETCompany ParticipantsAndrew Faughnan - Vice President,...

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10% and 0.13%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[544267]**

Amicus Therapeutics reports FY Non-GAAP EPS of $0.24, revenue of $528.3M. Forecasts 17-24% revenue growth by 2025, targeting GAAP net income in H2 2025.

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ami

Besides Wall Street's top -and-bottom-line estimates for Amicus Therapeutics (FOLD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) executed a significant transaction involving Zymeworks Inc (ZYME), reducing its holdings by 261,448

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) made a notable acquisition by purchasing 7,197,951 shares of Silence Therapeutics PLC. This transac

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) executed a significant stock transaction by acquiring an additional 13,427,917 shares of RAPT Thera

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio), a prominent investment firm, executed a significant transaction involving Pliant Therapeutics Inc

Overview of the Recent Transaction On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) made a strategic move by acquiring 2,440,000 shares of Ante

Overview of the Recent Transaction On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) made a significant move by acquiring 84,000,000 shares of T

On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a significant transaction involving Biodesix Inc (BDSX). The firm added 4,500,000 sha